Over 1,000 Chemotherapy Protocols And Counting
New chemotherapy protocols are added weekly. All protocols are reviewed by Medical Oncologists and Hematologists.
New Protool: Nivolumab-AVD in Hodgkin Lymphoma
Phase III, randomized, controlled study (SWOG S1826) Previously untreated pts were ≥12 years (y) with stage 3-4 HL N-AVD (n=489) vs. BV-AVD (n=487)
New Indication: Adjuvant Abemaciclib in HR+ Breast Cancer
Phase III, randomized, open-label trial (monarchE) Hormone receptor-positive, HER2-negative, node-positive, early breast cancer at a high risk of recurrence Abemaciclib + ET (n=280
New Indication: Dabrafenib and Trametinib in bRAF V600E Mutant Glioma
Open-label, single-arm, phase 2, basket trial BRAFV600E mutation-positive high- low-grade glioma Prior radiotherapy and chemotherapy or chemoradiotherapy for high grade glioma Dabr
New Indication: Adjuvant Atezolizumab – Bevacizumab in HCC
Phase III, randomized, controlled, multicenter, open-label trial (İMbrave050) HCC pts at high risk of recurrence following resection or ablation. Atezolizumab + Bevacizumab q21 (n
New Drug: Pirtobrutinib in Mantle Cell Lymphoma
Open-label, multicenter, single-arm trial (BRUIN) Mantle cell lymphoma previously treated with a BTK inhibitor Pirtobrutinib (n=120)
New Drug: Glofitamab in Large B-Cell Lymphoma
Phase I-II, open-label, multicenter study Relapse or refractory large cell lymphoma Glofitamab (n=132)
New Drug: Retifanlimab in Advanced Merkel Cell Carcinoma
Open-label, multicenter, single-arm, phase 2 study Treatment naïve metastatic or recurrent locally advanced MCC Retifanlimab q28 (n=65)
New Reference: Trastuzumab Deruxtecan for her2-Positive Breast Cancer
Phase III, randomized, controlled, multicenter, open-label trial (DESTINY-Breast-02) HER2-positive, previously received trastuzumab-emtansine, unresectable or metastatic breast can
New Protocol: Nivolumab and Trabectedin in Advanced Soft Tissue Sarcoma
Prospective, explorative, two-group, non-randomized, phase II trial (NITraSarc) Advanced, previously treated lipo-leiomyosarcoma (Group A: GA) (n=43) and non-L-sarcomas (Group B:
Easiest Access to Our Chemotherapy Protocol Library
Download our mobile app on iOS or Android to easily access our cancer protocol library, calculate chemotherapy doses, staging library, and access to the reference summaries
